CA
NZ
UK
AU
IND
US
Candel Therapeutics (NASDAQ:CADL), a Needham, Massachusetts clinical-stage company developing off-the-shelf immunotherapies for cancer, is climbing in pre-market trading after closing Thursday at $10.16, down 2.68%. Shares are at $10.70, up 5.32%, and no new clinical or regulatory announcement has been identified for the session.
Ensign Group (NASDAQ:ENSG), the San Juan Capistrano, CaliforniaHolding Companybehind a network of skilled nursing and senior living operators, is edging higher in pre-market trading after a large batch ofAcquisitionannouncements. Shares are at $172.00, up 1.40% from Thursday's close of $169.63.
Johnson & Johnson (NYSE:JNJ) presented late breaking two year data from its Phase 3 ICONIC-TOTAL trial at the European Academy of Dermatology and Venereology Congress, evaluating ICOTYDE, a targeted oral peptide that blocks the IL-23 receptor, in adults and adolescents with plaque psoriasis affecting …
Kailera Therapeutics (NASDAQ:KLRA), a Waltham, Massachusetts clinical-stage biotech building an obesity pipeline around GLP-1-based injectable and oral drugs, is rising in pre-market trading after closing Thursday at $11.03. Shares are changing hands at $11.65, up 5.62%, though no new company announcement has been identified …
NANOBIOTIX (NASDAQ:NBTX), a late stage clinical biotechnology company developing physics based approaches to cancer and other major diseases, announced the appointment of Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026. Christ succeeds Bart Van Rhijn, who …
Novartis (NYSE:NVS) is edging higher in pre-market trading after announcing the licensing agreement with Abogen. Shares are at $142.17, up 0.79% from Thursday's close of $141.05, a muted reaction for a deal with a headline value of up to $7.8 billion.
Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) announced that the European Medicines Agency has validated its Marketing Authorisation Application for rebisufligene etisparvovec, an investigational single dose gene therapy designed to treat MPS IIIA, more commonly known as Sanfilippo syndrome Type A. Validation confirms the application is sufficiently …
Nasdaq said after Thursday's close that Moderna will replace Warner Bros. Discovery in the Nasdaq-100 before the open on October 9. Moderna has more than sextupled this year, making it the S&P 500's second-best performer. Retail traders on social platforms used the news to …
Eli Lilly and Company (NYSE: LLY) is slipping modestly on Thursday as sellers keep control of a stock that has spent six weeks failing to hold above its moving averages. As of this chart snapshot (about 30 minutes before the close), shares are trading …
Merck & Co., Inc. (NYSE: MRK) is under pressure on Thursday, extending a pullback from its late-August high. As of this chart snapshot (about 30 minutes before the close), shares are trading at $143.49, down $1.82 (-1.26%). The stock opened at $144.71, traded to …
Please wait processing your request...